Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties.
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **LGS:** Initial dose: 5 mg twice daily. Increase by 5 mg to 10 mg every week as needed, not to exceed a total daily dose of 20 mg twice daily.
## Pediatric Dosing (2 to less than 10 years of age, or weighing less than 30 kg)
* **LGS:** Initial dose: 2.5 mg twice daily. Increase by 2.5 mg to 5 mg every week as needed, not to exceed a total daily dose of 10 mg twice daily.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment recommended, but initiate at the lower end of the dosing range and titrate slowly.
* **Renal Impairment:** Use with caution. No specific dose adjustment recommended, but initiate at the lower end of the dosing range and titrate slowly.
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, upper respiratory tract infection, pneumonia, ataxia, drooling, vomiting.
* **Serious:** Serious skin reactions (e.g., Stevens-Johnson syndrome), suicidal behavior and ideation, respiratory depression, dependence and withdrawal symptoms, cognitive impairment, behavioral changes.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and profound CNS depression.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam plasma concentrations.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam plasma concentrations.
* **Anticonvulsants:** Monitor for changes in efficacy or toxicity of either agent.
## Monitoring
* Monitor for efficacy in seizure control.
* Monitor for adverse effects, particularly somnolence, behavioral changes, and signs of serious skin reactions.
* Monitor for signs of respiratory depression, especially when used with other CNS depressants.
* Assess for dependence and withdrawal symptoms upon discontinuation.
## Clinical Pearls
* Clobazam should be initiated at a low dose and titrated slowly to minimize adverse effects.
* Patients should be advised not to drive or operate heavy machinery until they know how clobazam affects them.
* Abrupt discontinuation can lead to withdrawal symptoms. Taper the dose gradually when discontinuing.
* Clobazam is a Schedule IV controlled substance.
***
*This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details and to ensure patient safety. Dosing may vary based on individual patient factors and local protocols.*
